ClinicalTrials.gg
Not yet recruitingNCT07842679Updated Sep 28, 2026

Cognitive Impairment in Older Adults With Hematologic Malignancies

An observational study in Cognitive Impairment, Hematologic Malignancies and Chemotherapy Effect, sponsored by Assiut University. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Assiut University · Observational

How we know

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
120
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cognitive Dysfunction by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Assiut University.

Started
2026
with 3 others
Observational
8 of 10
6 open now
Registered
9th of 10
by date

Among the 10 studies in Cognitive Dysfunction by Assiut University, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

6 of the 10 studies in Cognitive Dysfunction by Assiut University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cognitive Dysfunction by Assiut University, or all of them as a file.
02

Study summary

This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.

Read the detailed description

Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.

Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).

03

Conditions studied

  • Cognitive Impairment
  • Hematologic Malignancies
  • Chemotherapy Effect

Keywords

  • Cognitive impairment
  • Hematologic malignancies
  • Assiut
  • MoCA
  • Activities of daily living
  • Older adults
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age 65 years or older
  • Confirmed diagnosis of hematologic
  • Currently receiving chemotherapy
  • Able to communicate and participate in cognitive assessment
  • Written

Exclusion criteria

Exclusion Criteria:

  • - Previously diagnosed dementia before the diagnosis of
  • Delirium at the time of assessment
  • Severe visual or hearing impairment interfering with cognitive testing
  • History of major neurological disorders affecting cognition
  • Severe psychiatric illness affecting cognitive assessment
  • Critically ill patients unable to complete study assessment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Older adults with hematologic malignancies

    Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment.

06

What researchers measure

Primary outcomes

  1. Prevalence of cognitive impairment

    Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.

    Time frame: Baseline

Secondary outcomes

  1. Mean MoCA score

    Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition)..

    Time frame: Baseline

  2. Mean Katz ADL score

    Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence).

    Time frame: Baseline

  3. Mean Lawton IADL score

    Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence)

    Time frame: Baseline

  4. Proportion with impaired activities of daily living

    Proportion of participants with impaired Katz ADL score.

    Time frame: Baseline

  5. Proportion with impaired instrumental activities of daily living

    Proportion of participants with impaired Lawton IADL score.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Feb 25, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionMean Katz ADL score: how it is measured was reworded
  • DescriptionMean Lawton IADL score: how it is measured was reworded
  • DescriptionMean MoCA score: how it is measured was reworded
Sep 28, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 2 updates
  1. Sep 28, 2026
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionMean Katz ADL score: how it is measured was reworded
    • DescriptionMean Lawton IADL score: how it is measured was reworded
    • DescriptionMean MoCA score: how it is measured was reworded
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842679
Lead sponsor
Assiut University
Responsible party
Khloud Khaled Fawzy Kotby (Resident Physician, Department of Internal Medicine - Geriatrics, Assiut University) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Kholoud K Fawzy, Resident
Contact
khloud.18313604@med.aun.edu.eg
01009850621
Soher M kasem, prof
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion